Innovative approaches to asthma treatment: harnessing nanoparticle technology
Source abstract
Abstract
In the domain of respiratory illnesses, asthma remains a critical obstacle. The heterogeneous nature of this chronic inflammatory disease poses challenges during its treatment. Glucocorticoid-based combination drug therapy now dominates clinical treatments for asthma; however, glucocorticoid resistance, numerous adverse effects, the incidence of inadequate drug delivery, and other factors need the development of more effective therapies. In recent years, there has been extensive research on nanotechnology in medicine. It has been shown in studies that these drug delivery systems can greatly enhance targeting and bioavailability and decrease the toxicity of medication. Nanoparticle drug delivery systems offer improved therapeutic efficacy compared to conventional administration techniques. Nanotechnology enables advancements in precision medicine, offering benefits for heterogeneous conditions such as asthma. This review will examine the critical factors of asthma to consider when formulating medications, as well as the role of nanomaterials and their mechanisms of action in pulmonary medicine for asthma treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Asthma and respiratory diseases · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184(9):2521–2. https://doi.org/10.1016/j.cell.2021.04.019.10.1016/j.cell.2021.04.019 ↗
2. Schoettler N, Strek ME. Recent advances in severe asthma: from phenotypes to personalized medicine. Chest. 2020;157(3):516–28. https://doi.org/10.1016/j.chest.2019.10.009.10.1016/j.chest.2019.10.009 ↗
3. Zuo X, Guo X, Gu Y, Zheng H, Zhou Z, Wang X, Jiang S, Wang G, Xu C, Wang F. Recent advances in nanomaterials for asthma treatment. Int J Mol Sci. 2022;23(22):14427. https://doi.org/10.3390/ijms232214427.10.3390/ijms232214427 ↗
4. Miller RL, Grayson MH, Strothman K. Advances in asthma: new understandings of asthma’s natural history, risk factors, underlying mechanisms, and clinical management. J Allergy Clin Immunol. 2021;148(6):1430–41. https://doi.org/10.1016/j.jaci.2021.10.001.10.1016/j.jaci.2021.10.001 ↗
5. Lee SW, Yon DK, James CC, Lee S, Koh HY, Sheen YH, Oh JW, Han MY, Sugihara G. Short-term effects of multiple outdoor environmental factors on risk of asthma exacerbations: age-stratified time-series analysis. J Allergy Clin Immunol. 2019;144(6):1542-1550.e1. https://doi.org/10.1016/j.jaci.2019.08.037.10.1016/j.jaci.2019.08.037 ↗
6. Lin SC, Shi LS, Ye YL. Advanced molecular knowledge of therapeutic drugs and natural products focusing on inflammatory cytokines in asthma. Cells. 2019;8(7):685. https://doi.org/10.3390/cells8070685.10.3390/cells8070685 ↗
7. Mathis BJ, Kusumoto M, Zaboronok A, Hiramatsu Y. Packaging and delivery of asthma therapeutics. Pharmaceutics. 2021;14(1):92. https://doi.org/10.3390/pharmaceutics14010092.10.3390/pharmaceutics14010092 ↗
8. Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, Durazzo A, Lucarini M, Eder P, Silva AM, Santini A, Souto EB. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Mol (Basel, Switz). 2020;25(16):3731. https://doi.org/10.3390/molecules25163731.10.3390/molecules25163731 ↗
9. Durack J, Christian LS, Nariya S, Gonzalez J, Bhakta NR, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Peters SP, Rosenberg SR, Sorkness CA, Wechsler ME, Wenzel SE, White SR, Lynch SV. Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma. J Allerg Clinic Immunol. 2020;146(5):1016–26. https://doi.org/10.1016/j.jaci.2020.03.028.10.1016/j.jaci.2020.03.028 ↗
10. Hauptman M, Gaffin JM, Petty CR, Sheehan WJ, Lai PS, Coull B, Gold DR, Phipatanakul W. Proximity to major roadways and asthma symptoms in the school inner-City asthma study. J Allergy Clin Immunol. 2020;145(1):119-126.e4. https://doi.org/10.1016/j.jaci.2019.08.038.10.1016/j.jaci.2019.08.038 ↗
11. McCauley K, Durack J, Valladares R, Fadrosh DW, Lin DL, Calatroni A, LeBeau PK, Tran HT, Fujimura KE, LaMere B, Merana G, Lynch K, Cohen RT, Pongracic J, Khurana Hershey GK, Kercsmar CM, Gill M, Liu AH, Kim H, Kattan M. Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. J Allerg Clinic Immunol. 2019;144(5):1187–97. https://doi.org/10.1016/j.jaci.2019.05.035.10.1016/j.jaci.2019.05.035 ↗
12. Sharma A, Laxman B, Naureckas ET, Hogarth DK, Sperling AI, Solway J, Ober C, Gilbert JA, White SR. Associations between fungal and bacterial microbiota of airways and asthma endotypes. J Allergy Clin Immunol. 2019;144(5):1214-1227.e7. https://doi.org/10.1016/j.jaci.2019.06.025.10.1016/j.jaci.2019.06.025 ↗
13. Patrick DM, Sbihi H, Dai DLY, Al Mamun A, Rasali D, Rose C, Marra F, Boutin RCT, Petersen C, Stiemsma LT, Winsor GL, Brinkman FSL, Kozyrskyj AL, Azad MB, Becker AB, Mandhane PJ, Moraes TJ, Sears MR, Subbarao P, Finlay BB, Turvey SE. Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies. Lancet Respirat Med. 2020;8(11):1094–105. https://doi.org/10.1016/S2213-2600(20)30052-7.10.1016/S2213-2600(20)30052-7 ↗
14. Dai X, Dharmage SC, Abramson MJ, Erbas B, Bennett CM, Svanes C, Hui J, Axelrad C, Lowe AJ, Lodge CJ. Early life acetaminophen exposure, glutathione S-transferase genes, and development of adolescent asthma in a high-risk birth cohort. J Allergy Clin Immunol. 2020;146(5):1035-1044.e12. https://doi.org/10.1016/j.jaci.2020.03.027.10.1016/j.jaci.2020.03.027 ↗
15. Sordillo JE, Rifas-Shiman SL, Switkowski K, Coull B, Gibson H, Rice M, Platts-Mills TAE, Kloog I, Litonjua AA, Gold DR, Oken E. Prenatal oxidative balance and risk of asthma and allergic disease in adolescence. J Allergy Clin Immunol. 2019;144(6):1534-1541.e5. https://doi.org/10.1016/j.jaci.2019.07.044.10.1016/j.jaci.2019.07.044 ↗
16. Rosa MJ, Hartman TJ, Adgent M, Gardner K, Gebretsadik T, Moore PE, Davis RL, LeWinn KZ, Bush NR, Tylavsky F, Wright RJ, Carroll KN. Prenatal polyunsaturated fatty acids and child asthma: effect modification by maternal asthma and child sex. J Allergy Clin Immunol. 2020;145(3):800-807.e4. https://doi.org/10.1016/j.jaci.2019.10.039.10.1016/j.jaci.2019.10.039 ↗
17. Kumar R, Ferrie RP, Balmert LC, Kienzl M, Rifas-Shiman SL, Gold DR, Sordillo JE, Kleinman K, Camargo CA Jr, Litonjua AA, Oken E, Cook-Mills JM. Associations of α- and γ-tocopherol during early life with lung function in childhood. J Allergy Clin Immunol. 2020;146(6):1349-1357.e3. https://doi.org/10.1016/j.jaci.2020.04.019.10.1016/j.jaci.2020.04.019 ↗
18. Permaul P, Gaffin JM, Petty CR, Baxi SN, Lai PS, Sheehan WJ, Camargo CA Jr, Gold DR, Phipatanakul W. Obesity may enhance the adverse effects of NO2 exposure in urban schools on asthma symptoms in children. J Allergy Clin Immunol. 2020;146(4):813-820.e2. https://doi.org/10.1016/j.jaci.2020.03.003.10.1016/j.jaci.2020.03.003 ↗
19. Zhu Z, Guo Y, Shi H, Liu CL, Panganiban RA, Chung W, O’Connor LJ, Himes BE, Gazal S, Hasegawa K, Camargo CA Jr, Qi L, Moffatt MF, Hu FB, Lu Q, Cookson WOC, Liang L. Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK biobank. J Allergy Clin Immunol. 2020;145(2):537–49. https://doi.org/10.1016/j.jaci.2019.09.035.10.1016/j.jaci.2019.09.035 ↗
20. Lambrecht BN, Hammad H. The immunology of the allergy epidemic and the hygiene hypothesis. Nat Immunol. 2017;18(10):1076–83. https://doi.org/10.1038/ni.3829.10.1038/ni.3829 ↗
21. Pakkasela J, Ilmarinen P, Honkamäki J, Tuomisto LE, Andersén H, Piirilä P, Hisinger-Mölkänen H, Sovijärvi A, Backman H, Lundbäck B, Rönmark E, Kankaanranta H, Lehtimäki L. Age-specific incidence of allergic and non-allergic asthma. BMC Pulm Med. 2020;20(1):9. https://doi.org/10.1186/s12890-019-1040-2.10.1186/s12890-019-1040-2 ↗
22. Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017;8(8):647–61. https://doi.org/10.4155/tde-2017-0037.10.4155/tde-2017-0037 ↗
23. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, Sakagami M, Vanbever R, Ehrhardt C. The particle has landed–characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 2):S71–87. https://doi.org/10.1089/jamp.2010.0836.10.1089/jamp.2010.0836 ↗
24. Yu CP. Exact analysis of aerosol deposition during steady breathing. Powder Technol. 1978;21(1):55–62. https://doi.org/10.1016/0032-5910(78)80107-7.10.1016/0032-5910(78)80107-7 ↗
25. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discovery. 2007;6(1):67–74. https://doi.org/10.1038/nrd2153.10.1038/nrd2153 ↗
26. Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discovery. 2005;4(5):381–5. https://doi.org/10.1038/nrd1721.10.1038/nrd1721 ↗
27. Chao P, Deshmukh M, Kutscher HL, Gao D, Rajan SS, Hu P, Laskin DL, Stein S, Sinko PJ. Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anticancer Drugs. 2010;21(1):65–76. https://doi.org/10.1097/CAD.0b013e328332a322.10.1097/CAD.0b013e328332a322 ↗
28. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338–44. https://doi.org/10.1513/pats.200409-049TA.10.1513/pats.200409-049TA ↗
29. Yamauchi K, Ogasawara M. The role of histamine in the pathophysiology of asthma and the clinical efficacy of antihistamines in asthma therapy. Int J Mol Sci. 2019;20(7):1733. https://doi.org/10.3390/ijms20071733.10.3390/ijms20071733 ↗
30. Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond). 2010;5(2):287–306. https://doi.org/10.2217/nnm.09.110.10.2217/nnm.09.110 ↗
31. Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Controll Release: Off J Controll Release Soc. 2003;86(1):131–44. https://doi.org/10.1016/s0168-3659(02)00370-x.10.1016/s0168-3659(02)00370-x ↗
32. Deeba F, Umer F, Nainan D. Applications of nanoparticles in treatment of respiratory disorders. Life Sci. 2022;3(1):49–56. https://doi.org/10.37185/LnS.1.1.186.10.37185/LnS.1.1.186 ↗
33. Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Controll Release: Off J Controll Release Soc. 2014;190:15–28. https://doi.org/10.1016/j.jconrel.2014.03.053.10.1016/j.jconrel.2014.03.053 ↗
34. Wang J, Wang P, Shao Y, He D. Advancing treatment strategies: a comprehensive review of drug delivery innovations for chronic inflammatory respiratory diseases. Pharmaceutics. 2023;15(8):2151. https://doi.org/10.3390/pharmaceutics15082151.10.3390/pharmaceutics15082151 ↗
35. Caminade AM. Dendrimers, an emerging opportunity in personalized medicine? J Personal Med. 2022;12(8):1334. https://doi.org/10.3390/jpm12081334.10.3390/jpm12081334 ↗
36. Zheng Y, Zhao Y, Bai M, Gu H, Li X. Metal-organic frameworks as a therapeutic strategy for lung diseases. J Mater Chem B. 2022;10(30):5666–95. https://doi.org/10.1039/d2tb00690a.10.1039/d2tb00690a ↗
37. Zhong W, Zhang X, Zeng Y, Lin D, Wu J. Recent applications and strategies in nanotechnology for lung diseases. Nano Res. 2021;14(7):2067–89. https://doi.org/10.1007/s12274-020-3180-3.10.1007/s12274-020-3180-3 ↗
38. Taghavizadeh Yazdi ME, Qayoomian M, Beigoli S, Boskabady MH. Recent advances in nanoparticle applications in respiratory disorders: a review. Front Pharmacol. 2023;14:1059343. https://doi.org/10.3389/fphar.2023.1059343.10.3389/fphar.2023.1059343 ↗
39. Nasr M, Najlah M, D’Emanuele A, Elhissi A. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int J Pharm. 2014;461(1–2):242–50. https://doi.org/10.1016/j.ijpharm.2013.11.023.10.1016/j.ijpharm.2013.11.023 ↗
40. Bhavna, Ahmad FJ, Mittal G, Jain GK, Malhotra G, Khar RK, Bhatnagar A. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm: Off J Arb Pharm Verfahr. 2009;71(2):282–91. https://doi.org/10.1016/j.ejpb.2008.09.018.10.1016/j.ejpb.2008.09.018 ↗
41. da Silva AL, Silva LA, Cruz FF, Rocco PRM, Morales MM. Application of novel nanotechnologies in asthma. Ann Trans Med. 2020;8(5):159. https://doi.org/10.21037/atm.2019.2.40.10.21037/atm.2019.2.40 ↗
42. Keil TW, Feldmann DP, Costabile G, Zhong Q, da Rocha S, Merkel OM. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles. Eur J Pharm Biopharm. 2019;143:61–9. https://doi.org/10.1016/j.ejpb.2019.08.012.10.1016/j.ejpb.2019.08.012 ↗
43. Keil TW, Baldassi D, Merkel OM. T-cell targeted pulmonary siRNA delivery for the treatment of asthma. Wiley Interdiscip Rev: Nanomed Nanobiotechnol. 2020;12(5):e1634. https://doi.org/10.1002/wnan.1634.10.1002/wnan.1634 ↗
44. Chen J, Tang Y, Liu Y, et al. Nucleic acid-based therapeutics for pulmonary diseases. AAPS PharmSciTech. 2018;19:3670–80. https://doi.org/10.1208/s12249-018-1183-0.10.1208/s12249-018-1183-0 ↗
45. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20(2):101–24. https://doi.org/10.1038/s41573-020-0090-8.10.1038/s41573-020-0090-8 ↗
46. Chen X, Huang W, Wong BC, Yin L, Wong YF, Xu M, Yang Z. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomed. 2012;7:1139–48. https://doi.org/10.2147/IJN.S28011.10.2147/IJN.S28011 ↗
47. Keil TWM, Feldmann DP, Costabile G, Zhong Q, da Rocha S, Merkel OM. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles. Eur J Pharm Biopharm: Off J Arb Pharm Verfahr. 2019;143:61–9. https://doi.org/10.1016/j.ejpb.2019.08.012.10.1016/j.ejpb.2019.08.012 ↗
48. Wang K, Feng Y, Li S, Li W, Chen X, Yi R, Zhang H, Hong Z. Oral delivery of bavachinin-loaded PEG-PLGA nanoparticles for asthma treatment in a murine model. J Biomed Nanotechnol. 2018;14(10):1806–15. https://doi.org/10.1166/jbn.2018.2618.10.1166/jbn.2018.2618 ↗
49. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M, Yamashita N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol. 2009;260(1):33–8. https://doi.org/10.1016/j.cellimm.2009.07.004.10.1016/j.cellimm.2009.07.004 ↗
50. Joshi VB, Adamcakova-Dodd A, Jing X, Wongrakpanich A, Gibson-Corley KN, Thorne PS, Salem AK. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS J. 2014;16(5):975–85. https://doi.org/10.1208/s12248-014-9624-5.10.1208/s12248-014-9624-5 ↗
51. Salem AK. A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies. Immunotherapy. 2014;6(11):1161–3. https://doi.org/10.2217/imt.14.97.10.2217/imt.14.97 ↗
52. Kenyon NJ, Bratt JM, Lee J, Luo J, Franzi LM, Zeki AA, Lam KS. Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation. PLoS ONE. 2013;8(10):e77730. https://doi.org/10.1371/journal.pone.0077730.10.1371/journal.pone.0077730 ↗
53. Kumar M, Kong X, Behera AK, Hellermann GR, Lockey RF, Mohapatra SS. Chitosan IFN-gamma-pDNA nanoparticle (CIN) therapy for allergic asthma. Genet Vaccin Ther. 2003;1(1):3. https://doi.org/10.1186/1479-0556-1-3.10.1186/1479-0556-1-3 ↗
54. Kong X, Hellermann GR, Zhang W, Jena P, Kumar M, Behera A, Behera S, Lockey R, Mohapatra SS. Chitosan Interferon-gamma nanogene therapy for lung disease: modulation of T-Cell and dendritic cell immune responses. Allerg Asthma Clinic Immunol: Off J Can Soc Allerg Clinic Immunol. 2008;4(3):95–105. https://doi.org/10.1186/1710-1492-4-3-95.10.1186/1710-1492-4-3-95 ↗
55. Grozdanovic M, Laffey KG, Abdelkarim H, Hitchinson B, Harijith A, Moon HG, Park GY, Rousslang LK, Masterson JC, Furuta GT, Tarasova NI, Gaponenko V, Ackerman SJ. Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness. J Allergy Clin Immunol. 2019;143(2):669-680.e12. https://doi.org/10.1016/j.jaci.2018.05.003.10.1016/j.jaci.2018.05.003 ↗
56. Bhavna, Ahmad FJ, Mittal G, Jain GK, Malhotra G, Khar RK, Bhatnagar A. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm: Off J Arb Pharm Verfahr. 2009;71(2):282–91. https://doi.org/10.1016/j.ejpb.2008.09.018.10.1016/j.ejpb.2008.09.018 ↗
57. Arafa MG, Ayoub BM. Bioavailability study of niosomal salbutamol sulfate in metered dose inhaler: controlled pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv. 2018;31(2):114–5. https://doi.org/10.1089/jamp.2017.1448.10.1089/jamp.2017.1448 ↗
58. Chakraborty S, Ehsan I, Mukherjee B, Mondal L, Roy S, Saha KD, Paul B, Debnath MC, Bera T. Therapeutic potential of andrographolide-loaded nanoparticles on a murine asthma model. Nanomed Nanotechnol Biol Med. 2019;20:102006. https://doi.org/10.1016/j.nano.2019.04.009.10.1016/j.nano.2019.04.009 ↗
59. Patel KK, Tripathi M, Pandey N, Agrawal AK, Gade S, Anjum MM, Tilak R, Singh S. Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis. Int J Pharm. 2019;563:30–42. https://doi.org/10.1016/j.ijpharm.2019.03.051.10.1016/j.ijpharm.2019.03.051 ↗
60. Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int J Pharm. 2009;381(2):122–9. https://doi.org/10.1016/j.ijpharm.2009.04.009.10.1016/j.ijpharm.2009.04.009 ↗
61. Wang J, Xian M, Cao H, Wu L, Zhou L, Ma Y, Fan L, Lin L, Li G, Huang Q, Huang SK, Xiao X. Prophylactic and therapeutic potential of magnolol-loaded PLGA-PEG nanoparticles in a chronic murine model of allergic asthma. Front Bioeng Biotechnol. 2023;11:1182080. https://doi.org/10.3389/fbioe.2023.1182080.10.3389/fbioe.2023.1182080 ↗
62. Ouyang S, Lu P, Li J, Jin H, Wu W, Luo R, Wang B, Huang X, Lian X, Huang G. Inhaled tea polyphenol-loaded nanoparticles coated with platelet membranes largely attenuate asthmatic inflammation. Respir Res. 2024;25(1):311. https://doi.org/10.1186/s12931-024-02947-3.10.1186/s12931-024-02947-3 ↗
63. Fatima R, Sharma M, Prasher P. Role of Dendrimers in Management of Allergic Airway Diseases. In: Prasher P, Sharma M, Singh SK, MacLoughlin R, Pabreja K, Dua K, editors. Understanding Allergic Airway Diseases. Singapore: Springer; 2024. https://doi.org/10.1007/978-981-97-1953-2_12.10.1007/978-981-97-1953-2_12 ↗
64. Conti DS, Brewer D, Grashik J, Avasarala S, da Rocha SR. Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm. 2014;11(6):1808–22. https://doi.org/10.1021/mp4006358.10.1021/mp4006358 ↗
65. Chytil P, Kostka L, Etrych T. HPMA copolymer-based nanomedicines in controlled drug delivery. J Person Med. 2021;11(2):115. https://doi.org/10.3390/jpm11020115.10.3390/jpm11020115 ↗
66. Kumar M, Jha A, Bharti K, Parmar G, Mishra B. Advances in lipid-based pulmonary nanomedicine for the management of inflammatory lung disorders. Nanomedicine. 2022;17(12):913–34. https://doi.org/10.2217/nnm-2021-0389.10.2217/nnm-2021-0389 ↗
67. Zhang M, Jiang H, Wu L, Lu H, Bera H, Zhao X, Yang M. Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment. J Controll Release. 2022;352:422–37. https://doi.org/10.1016/j.jconrel.2022.10.020.10.1016/j.jconrel.2022.10.020 ↗
68. Xu X, Wang Y, Luo X, Gao X, Gu W, Ma Y, Dong L. A non-invasive strategy for suppressing asthmatic airway inflammation and remodeling: Inhalation of nebulized hypoxic hUCMSC-derived extracellular vesicles. Front Immunol. 2023;14:1150971. https://doi.org/10.3389/fimmu.2023.1150971.10.3389/fimmu.2023.1150971 ↗
69. Dong L, Wang Y, Zheng T, Pu Y, Ma Y, Qi X, Mao C. Hypoxic hUCMSC-derived extracellular vesicles attenuate allergic airway inflammation and airway remodeling in chronic asthma mice. Stem Cell Res Therapy. 2021;12:1–14. https://doi.org/10.1186/s13287-020-02072-0.10.1186/s13287-020-02072-0 ↗
70. Mughal SS. Diagnosis and treatment of diseases by using metallic nanoparticles-a review. Authorea Preprints. 2022. https://doi.org/10.22541/au.166401168.84305772/v1.10.22541/au.166401168.84305772/v1 ↗
71. Wen R, Umeano AC, Chen P, Farooqi AA. Polymer-based drug delivery systems for cancer. Crit Rev Ther Drug Carrier Syst. 2018;35(6):521–53. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018021124.10.1615/CritRevTherDrugCarrierSyst.2018021124 ↗
72. d’Angelo I, Conte C, Miro A, Quaglia F, Ungaro F. Pulmonary drug delivery: a role for polymeric nanoparticles? Curr Top Med Chem. 2015;15(4):386–400. https://doi.org/10.2174/1568026615666150108123256.10.2174/1568026615666150108123256 ↗
73. Reshma VG, Syama S, Sruthi S, Reshma SC, Remya NS, Mohanan PV. Engineered nanoparticles with antimicrobial property. Curr Drug Metab. 2017;18(11):1040–54. https://doi.org/10.2174/1389200218666170925122201.10.2174/1389200218666170925122201 ↗
74. Mohebbi S, Nezhad MN, Zarrintaj P, Jafari SH, Gholizadeh SS, Saeb MR, Mozafari M. Chitosan in biomedical engineering: a critical review. Curr Stem Cell Res Ther. 2019;14(2):93–116. https://doi.org/10.2174/1574888X13666180912142028.10.2174/1574888X13666180912142028 ↗
75. Islam N, Ferro V. Recent advances in chitosan-based nanoparticulate pulmonary drug delivery. Nanoscale. 2016;8(30):14341–58. https://doi.org/10.1039/c6nr03256g.10.1039/c6nr03256g ↗
76. Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, Qoronfleh MW. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):20. https://doi.org/10.1186/s40824-019-0166-x.10.1186/s40824-019-0166-x ↗
77. El-Hammadi MM, Arias JL. Recent advances in the surface functionalization of PLGA-based nanomedicines. Nanomater (Basel, Switz). 2022;12(3):354. https://doi.org/10.3390/nano12030354.10.3390/nano12030354 ↗
78. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Investig. 2019;129(4):1493–503. https://doi.org/10.1172/JCI124611.10.1172/JCI124611 ↗
79. Boltnarova B, Kubackova J, Skoda J, Stefela A, Smekalova M, Svacinova P, Pavkova I, Dittrich M, Scherman D, Zbytovska J, Pavek P, Holas O. PLGA based nanospheres as a potent macrophage-specific drug delivery system. Nanomaterials (Basel, Switzerland). 2021;11(3):749. https://doi.org/10.3390/nano11030749.10.3390/nano11030749 ↗
80. Ryan GM, Kaminskas LM, Kelly BD, Owen DJ, McIntosh MP, Porter CJ. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Mol Pharm. 2013;10(8):2986–95. https://doi.org/10.1021/mp400091n.10.1021/mp400091n ↗
81. Hemmelmann M, Metz VV, Koynov K, Blank K, Postina R, Zentel R. Amphiphilic HPMA-LMA copolymers increase the transport of Rhodamine 123 across a BBB model without harming its barrier integrity. J Controll Release: Off J Controll Release Soc. 2012;163(2):170–7. https://doi.org/10.1016/j.jconrel.2012.08.034.10.1016/j.jconrel.2012.08.034 ↗
82. Kopecek J, Kopecková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev. 2010;62(2):122–49. https://doi.org/10.1016/j.addr.2009.10.004.10.1016/j.addr.2009.10.004 ↗
83. Paliwal R, Paliwal SR, Kenwat R, Kurmi BD, Sahu MK. Solid lipid nanoparticles: a review on recent perspectives and patents. Expert Opin Ther Pat. 2020;30(3):179–94. https://doi.org/10.1080/13543776.2020.1720649.10.1080/13543776.2020.1720649 ↗
84. Wagner N, Eberhardt M, Vera J, Cuomo F, Blume K, Galster S, Achenbach S, Laffert B, Kahlert H, Schuler G, Berking C, Baur A. Plasma-derived extracellular vesicles discriminate type-1 allergy subjects from non-allergic controls. World Allerg Organ J. 2021;14(9):100583. https://doi.org/10.1016/j.waojou.2021.100583.10.1016/j.waojou.2021.100583 ↗
85. Beegle J, Lakatos K, Kalomoiris S, Stewart H, Isseroff RR, Nolta JA, Fierro FA. Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo. Stem Cells (Dayton, Ohio). 2015;33(6):1818–28. https://doi.org/10.1002/stem.1976.10.1002/stem.1976 ↗
86. Park HS, Kim KH, Jang S, Park JW, Cha HR, Lee JE, Jung SS. Attenuation of allergic airway inflammation and hyperresponsiveness in a murine model of asthma by silver nanoparticles. Int J Nanomed. 2010. https://doi.org/10.2147/IJN.S11664.10.2147/IJN.S11664 ↗
87. Jang S, Park JW, Cha HR, Jung SY, Lee JE, Jung SS, Park HS. Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation. Int J Nanomed. 2012;7:1329–43.
88. Park HS, Kim KH, Jang S, Park JW, Cha HR, Lee JE, Jung SS. Attenuation of allergic airway inflammation and hyperresponsiveness in a murine model of asthma by silver nanoparticles. Int J Nanomed. 2010;5:505–15.10.2147/IJN.S11664 ↗
89. Li Z, Tian C, Jiao D, Li J, Li Y, Zhou X, Han X. Synergistic effects of silver nanoparticles and cisplatin in combating inflammation and hyperplasia of airway stents. Bioact Mater. 2022;9:266–80.
90. Su CL, Chen TT, Chang CC, Chuang KJ, Wu CK, Liu WT, Cheng TJ. Comparative proteomics of inhaled silver nanoparticles in healthy and allergen provoked mice. Int J Nanomed. 2013;8:2783–99.
91. Jang S, Park JW, Cha HR, Jung SY, Lee JE, Jung SS, Kim JO, Kim SY, Lee CS, Park HS. Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation. Int J Nanomed. 2012;7:1329–43. https://doi.org/10.2147/IJN.S27159.10.2147/IJN.S27159 ↗
92. Ávalos A, Haza AI, Mateo D, Morales P. Effects of silver and gold nanoparticles of different sizes in human pulmonary fibroblasts. Toxicol Mech Methods. 2015;25(4):287–95.10.3109/15376516.2015.1025347 ↗
93. Talarska P, Boruczkowski M, Żurawski J. Current knowledge of silver and gold nanoparticles in laboratory research—application, toxicity, cellular uptake. Nanomaterials. 2021;11(9):2454.10.3390/nano11092454 ↗
94. Barreto E, Serra MF, Dos Santos RV, Dos Santos CEA, Hickmann J, Cotias AC, Martins MA. Local administration of gold nanoparticles prevents pivotal pathological changes in murine models of atopic asthma. J Biomed Nanotechnol. 2015;11(6):1038–50.10.1166/jbn.2015.2024 ↗
95. Omlor AJ, Le DD, Schlicker J, Hannig M, Ewen R, Heck S, Dinh QT. Local effects on airway inflammation and systemic uptake of 5 nm PEGylated and citrated gold nanoparticles in asthmatic mice. Small. 2017;13(10):1603070.10.1002/smll.201603070 ↗
96. Barreto E, Serra MF, Dos Santos RV, Dos Santos CE, Hickmann J, Cotias AC, Pão CR, Trindade SG, Schimidt V, Giacomelli C, Carvalho VF, Rodrigues E, Silva PM, Cordeiro RS, Martins MA. Local administration of gold nanoparticles prevents pivotal pathological changes in murine models of atopic asthma. J Biomed Nanotechnol. 2015;11(6):1038–50. https://doi.org/10.1166/jbn.2015.2024.10.1166/jbn.2015.2024 ↗
97. Wu Y, Shi W, Wang H, Yue J, Mao Y, Zhou W, Wang Y. Anti-ST2 nanoparticle alleviates lung inflammation by targeting ILC2s-CD4+ T response. Int J Nanomed. 2020;15:9745–58.10.2147/IJN.S268282 ↗
98. Wu Y, Shi W, Wang H, Yue J, Mao Y, Zhou W, Kong X, Guo Q, Zhang L, Xu P, Wang Y. Anti-ST2 nanoparticle alleviates lung inflammation by targeting ILC2s-CD4+T response. Int J Nanomed. 2020;15:9745–58. https://doi.org/10.2147/IJN.S268282.10.2147/IJN.S268282 ↗
99. Garcia-Fernandez A, Sancenon F, Martinez-Manez R. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev. 2021;177:113953. https://doi.org/10.1016/j.addr.2021.113953.10.1016/j.addr.2021.113953 ↗
100. García-Fernández A, Sancenón F, Martínez-Máñez R. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev. 2021;177:113953. https://doi.org/10.1016/j.addr.2021.113953.10.1016/j.addr.2021.113953 ↗